
Establishing the CQAs of a mAb product by evaluating impact and uncertainty during risk assessment.
Andrew Weiskopf is director, technical development, Biogen Idec

Establishing the CQAs of a mAb product by evaluating impact and uncertainty during risk assessment.

Published: July 1st 2014 | Updated: